# Dosing & Timing
Dosing Boswellia in oncology is more complex than simply choosing a high milligram label.
The key variables are **AKBA content**, extract standardisation, and whether the product is taken with food.
### Core issue
Boswellia products differ widely in:
* AKBA percentage
* Total boswellic acids
* Overall extract quality
* Formulation type
Visit the [Sourcing Quality Boswellia page](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/sourcing-quality-boswellia.md) for detailed information on two trusted formulas available worldwide.
### General dosing logic
Clinical and integrative use often falls roughly into these bands:
* **general adjunctive support:** around 1,500–2,400 mg/day of standardised extract
* **human breast-cancer window trial anchor:** **2,400 mg/day** of BosPure® for about 2 weeks before surgery
* **brain tumour / radiation-oedema use:** typically around **3,600–4,500 mg/day** in divided doses, with **4,200 mg/day** as the clearest pilot-trial anchor
### Human dosing example — brain tumours and radiation-related cerebral oedema
The strongest practical dosing literature for Boswellia is actually in **brain tumours**, not breast cancer.
The clearest supportive-care anchor is the **Kirste pilot randomised trial** in patients receiving brain radiotherapy.
Key details:
* **setting:** brain tumours with radiation-related cerebral oedema
* **study design:** prospective, randomised, placebo-controlled, double-blind pilot trial
* **trial dose:** **4,200 mg/day** in divided doses
* **main result:** greater **MRI-visible oedema reduction** than placebo
* **clinical signal:** some neurologic improvement and steroid-sparing benefit
* **tolerability:** **4,200 mg/day** was reported as well tolerated
A later 2025 review of Boswellia for radiation-induced CNS toxicity summarised that most clinical neuro-oncology use falls around **3,600 to 4,500 mg/day** in divided doses.
That makes the brain-tumour literature the clearest example of **higher-dose supervised Boswellia use** in oncology.
{% hint style="warning" %}
A 2024 abstract described two patients who accidentally took about **42,000 mg/day** rather than **4,200 mg/day** and were still surprisingly tolerant.
That is not a recommended dose.
It is an anecdotal signal only.
{% endhint %}
### Human dosing example — 2024 breast-cancer window trial
The clearest **AKBA-standardised** Boswellia dosing anchor in human oncology is the 2024 Phase Ia breast-cancer window trial.
Key details:
* **product used:** BosPure® *Boswellia serrata* extract
* **capsule strength:** **400 mg**
* **standardisation:** **10% AKBA**
* **trial dose:** **2 capsules three times daily with food**
* **total daily extract:** **2,400 mg/day**
* **estimated daily AKBA:** about **240 mg/day**
* **duration:** the short period between biopsy and surgery, usually around 2 weeks
Key findings:
* tumour proliferation marker **Ki-67** fell significantly versus control
* the drop was about **13–14%**
* **no significant increase in apoptosis markers** was seen
* tolerability was good, with **no serious treatment-related adverse events** reported
This does **not** prove Boswellia treats breast cancer.
It does give a useful real-world reference point for how one human oncology study dosed a standardised AKBA-containing extract.
{% hint style="info" %}
#### AKBA comparison examples for published dose anchors
The BosPure® breast-cancer trial delivered about **240 mg AKBA per day**.
That makes **daily AKBA exposure** a more useful comparison point than raw Boswellia milligrams alone.
Using the product details currently listed on this site:
* To approximate the **breast-cancer trial anchor** of **240 mg AKBA/day**:
* **Boswellia MEGA AKBA Liposomal** — about **4 capsules/day**
* **Inflasanum** — about **2 capsules/day** reaches about **360 mg AKBA/day**, which is already **above** that anchor
* To approximate a **4,200 mg/day brain-oedema regimen** using a **10% AKBA-style extract**, the rough equivalent would be about **420 mg AKBA/day**
* **Boswellia MEGA AKBA Liposomal** — about **7 capsules/day**
* **Inflasanum** — about **3 capsules/day** reaches about **540 mg AKBA/day**, which is **above** that rough comparison point
Not all brain-oedema studies reported AKBA standardisation in the same way.
So the **420 mg AKBA/day** comparison is only a rough translation, not a strict dose conversion.
Higher-AKBA products may still reach research-style targets with fewer capsules and less total extract.
{% endhint %}
### Timing principles
* Take Liposomal Boswellia **20 minutes before food with a 200ml glass of water**
* Divided doses usually make more sense because of the modest half-life
* If combining with other CYP-active compounds, spacing them out may be warranted in some instances
### Practical takeaway
The better Boswellia dosing question is not just **How much Boswellia?**
It is:
* How much **standardised extract**
* How much **AKBA**
* How it is being **taken and absorbed**
* and what the **clinical goal** actually is
For the brain-tumour supportive-care data behind the higher-dose anchor, see [Glioblastoma & Brain Tumours](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/glioblastoma-and-brain-tumours.md).
For the human breast-cancer data behind the lower AKBA-standardised anchor, see [Breast Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/breast-cancer.md).
For high-AKBA product comparison, see [Sourcing Quality Boswellia](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/sourcing-quality-boswellia.md).
For safety review, see [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/safety-and-interactions.md).
### Key References
Enhanced Bioavailability of Boswellic Acid by Piper longum\
Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors\
Boswellia serrata for cerebral radiation necrosis after radiosurgery for brain metastases\
The anti-proliferative effects of a frankincense extract in a window of opportunity Phase Ia clinical trial for patients with breast cancer\
The anti-proliferative effects of a frankincense extract in a window of opportunity Phase Ia clinical trial for patients with breast cancer\
### Jump to another Boswellia page
**Core pages**
* [Boswellia in Oncology Overview](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-in-oncology-overview.md)
* [Evidence Summary](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/evidence-summary.md)
* [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/anticancer-mechanisms.md)
* [Boswellia Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type.md)
**Mechanism deep dives**
* [Redox Dual Action](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/redox-dual-action.md)
* [NRF2 Impact](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/nrf2-impact.md)
* [Ferroptosis Findings](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/ferroptosis-findings.md)
* [Immune Effects](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/immune-effects.md)
**Practical pages**
* [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/pharmacokinetics-and-metabolism.md)
* [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/safety-and-interactions.md)
* [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/synergistic-combinations.md)
* [Hydroxychloroquine + Boswellia](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/hydroxychloroquine-+-boswellia.md)
* [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/dosing-and-timing.md)
* [Sourcing Quality Boswellia](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/sourcing-quality-boswellia.md)
**Cancer-type pages**
* [Glioblastoma & Brain Tumours](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/glioblastoma-and-brain-tumours.md)
* [Breast Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/breast-cancer.md)
* [Colorectal Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/colorectal-cancer.md)
* [Pancreatic Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/pancreatic-cancer.md)
* [Prostate Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/prostate-cancer.md)
* [Non-Small Cell Lung Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/non-small-cell-lung-cancer.md)
* [Ovarian Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/ovarian-cancer.md)
* [Other Cancer Types](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/other-cancer-types.md)
{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}
{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/dosing-and-timing.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.